Treatment Outcome Clinical Trial
Official title:
99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis
Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.
The prevalence of osteoarthritis of the knee (OA) is increasing worldwide and this burden will continue to increase owing to aging of the general population 99Tc-MDP is effective for rheumatoid arthritis. Consequent to an increase in incidence is the rise in the number of patients with knee OA who are prone to further deterioration of the knee. It therefore is important to better understand, control, and attempt to prevent further progression of disease in patients with knee OA. Limitations in walking, stair climbing, and squatting are common patient complaints that greatly interfere with activities of daily living and recreation. Currently there is no definite consensus on the standardized management of OA. Oral analgesic and anti-inflammatory agents are perhaps the most commonly prescribed treatments to alleviate knee OA symptoms. The failure of nonsurgical therapies to modify quality of life in knee OA patients is not surprising given their inability to alleviate physical manifestations of OA. Surgical knee OA interventions generally result in good to excellent patient outcomes. However, there are significant barriers to considering surgery, which limits clinical utility. 99Tc-MDP is actually the decay product of 99mTc-MDP (99mTc-methylene diphosphonate, a US Food and Drug Administration-approved radioactive agent widely used for bone scintigraphy). 99Tc-MDP (Chengdu Yunke Pharmaceutical, Sichuan, China) is a kind of anti-inflammatory drug patented in China (patent no. ZL94113006.1). It was approved for production by the State Food and Drug Administration of China in October 1997. 99Tc-MDP has been demonstrated to be safe and effective in the clinical treatment of immune diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) and certain bone diseases, such as skeletal metastases from cancer in China. 99Tc-MDP also showed clinical effect on knee OA in our practice. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05411393 -
Synergizing Home Health Rehabilitation Therapy
|
N/A | |
Recruiting |
NCT05621356 -
Monitoring Allergen Immunotherapy in Allergic Rhinitis
|
||
Not yet recruiting |
NCT05593380 -
The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH
|
N/A | |
Recruiting |
NCT05964725 -
The Study on Effect and Neural Network Mechanism of Transcranial Direct Current Stimulation for Sudden Deafness With Tinnitus
|
N/A | |
Not yet recruiting |
NCT05417711 -
Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus
|
N/A | |
Recruiting |
NCT04013646 -
Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03477240 -
Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
|
||
Recruiting |
NCT06035783 -
Calcium Reduction by Orbital Atherectomy in Western Europe
|
||
Recruiting |
NCT05413707 -
Weber B Ankle Fractures With Associated Posterior Malleolus Fracture
|
N/A | |
Completed |
NCT01364649 -
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
|
Phase 3 | |
Completed |
NCT04682951 -
Good Prognosis Factors After Decompressive Craniectomy : a Ten-year Retrospective Study
|
||
Recruiting |
NCT05616559 -
Precision Medicine in the Depression Treatment
|
||
Recruiting |
NCT06441110 -
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT03223142 -
Standardization of Multi-modal Tumor Ablation Therapy System
|
N/A | |
Completed |
NCT05594160 -
Agentic Self-view as Common Factor in Psychotherapy - Self-efficacy in the Treatment of Inpatients Over the Course of Time
|
||
Recruiting |
NCT05851989 -
Study on Prognosis of Acutely Ruptured Intracranial Aneurysms
|
||
Not yet recruiting |
NCT05885919 -
Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
|
Phase 3 | |
Enrolling by invitation |
NCT06367829 -
Lubinus SPII Hip Stem Target Trial Emulation (LARGE)
|
||
Active, not recruiting |
NCT01235104 -
Impact of Total Nephrectomy on Patients With Kidney Stone
|
N/A | |
Completed |
NCT03638492 -
Trial of Surgical Excision Margins in Thick Primary Melanoma - 2
|
N/A |